K060717_ page 1

APR 1 3 2006

Attachment F

As Required by 807.92 For ViTelCareTM C-Turtle Patient Monitoring System Prepared on March 9th, 2006

Submitted By:

ViTel Net

8201 Greensboro Drive, Suite 600

McLean, VA 22102

Tel. (703) 448-0999

Fax: (703) 749-9559

Contact Person:

Allen Izadpanah

President and Chief Executive Officer

Device Trade Name:

ViTelCareTM C-Turtle Patient Monitoring System

Common Name:

C-Turtle Patient Monitoring System

Classification:

Not Classified

Predictive Device:

ViTelCareTM Patient Monitoring System (K040581)

ViTelCareTM Turtle 800 Patient Monitoring System

(C040283)

ViTel Care Turtle 400 Patient Monitoring System

(K043368)

Manufactured By:

ViTel Net

221 Elizabeth Street Utica, NY 13501

Description of The Device: The ViTel*Care* TM C-Turtle Patient Monitoring System is a PC based Telemedicine system adapted to the collection, management, and communication of patient monitoring data from home and group care environments.

Intended Use For This Device: Indications for Use: ViTelCareTM C-Turtle Patient Monitoring System is intended to be a communication tool for an in-home patient that acquires, accumulates, and transmits vital signs information, self-assessment of physical condition, and other physiological data to a healthcare practitioner located remotely from the patient. The patient information is received and stored on the MedVizerTM ViTelCare Call Center where a qualified healthcare practitioner can review the patient information and data. The healthcare practitioner can contact the patient directly through a videoconference connection when desired. The communication connectivity between

KOPCIIS bakes

patient and healthcare practitioner is via a standard public telecommunications utility to the Internet. Decisions concerning diagnosis and treatment are to be performed by qualified healthcare professionals.

Substantial Equivalence to Predicate Device: The ViTelCareTM C-Turtle Patient Monitoring System is virtually identical to the ViTelCareTM Turtle 400 Monitoring System with addition of videoconference functionality of the Turtle 800. There are no technical differences with any implications for safety and effectiveness. The labeling of ViTelCareTM C-Turtle Patient Monitoring System includes extensive protocols for monitoring patients with medical conditions. These have been derived from guidelines published by the VA, DoD, and other national organizations.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 1 9 2006

ViTel Net c/o Mr. Allen Izadpanah President and Chief Executive Officer 8201 Greensboro Drive, Suite 600 McLean, VA 22102

Re: K060712

Trade Name: ViTelCare™ C-Turtle Patient Monitoring System

Regulation Number: 21 CFR 870.2300

Regulation Name: Physiological Patient Monitor (without arrhythmia detection or alarms)

Regulatory Class: Class II (two)

Product Code: MWI Dated: March 16, 2006 Received: March 16, 2005

Dear Mr. Izadpanah:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Page 2 – Mr. Allen Izadpanah

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Blummamon for

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

K060712

Page 1021

Attachment B

Indications for Use

510(k) Number (if know	vn): <u>K0607</u> 12	
Device Name: <u>ViTel<i>Ca</i>r</u>	re TM C-Turtle Patient	Monitoring System
a communication tool for vital signs information, a data to a healthcare practinformation is received a qualified healthcare practitioner connection when desired healthcare practitioner is	or an in-home patient the self-assessment of physicitioner located remotel and stored on the MedV ctitioner can review the can contact the patient defended. The communication is via a standard public t	ient Monitoring System is intended to be at acquires, accumulates, and transmits ical condition, and other physiologically from the patient. The patient Vizer ViTel Care Call Center where a patient information and data. The irectly through a videoconference connectivity between patient and elecommunications utility to the Internet are to be performed by qualified healthcare
Prescription Use (Part 21 CFR 801 S	(A 1841 1/1 11s	Over-The-Counter Use(21 CFR 807 Subpart C)
(PLEASE DO NOT W	RITE BELOW THIS L OF NEEI	INE-CONTINUE ON ANOTHER PAGE DED)
Concurrence of CDRH,	Office of Device Evalu	ration (ODE)
Dymnum		
Division Sign-Off) Division of Cardiovase	ular D evices	

Villel Net To March 2009

510(k) Number K. CGOTA